Curis Inc (CRIS.O) Quote| Reuters.com
Edition:
United States

Curis Inc (CRIS.O)

CRIS.O on Consolidated Issue listed on NASDAQ Global Market

1.54USD
30 Jun 2016
Change (% chg)

$-0.01 (-0.96%)
Prev Close
$1.56
Open
$1.58
Day's High
$1.59
Day's Low
$1.54
Volume
167,965
Avg. Vol
405,027
52-wk High
$3.75
52-wk Low
$1.25

CRIS.O

Chart for CRIS.O

About

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $201.52
Shares Outstanding(Mil.): 129.18
Dividend: --
Yield (%): --

Financials

  CRIS.O Industry Sector
P/E (TTM): -- 41.10 35.71
EPS (TTM): -0.28 -- --
ROI: -39.98 -6.56 14.23
ROE: -50.95 -5.98 15.43

BRIEF-Curis reports Q1 loss of $0.07 per share

* Q1 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 09 2016

BRIEF-Curis Inc names new CFO

* Appointment of James E. Dentzer as chief financial and chief administrative officer

Mar 30 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.